rPlan Multimedia Dual Protection Intervention to Reduce Health Disparities
NCT02498067 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 104
Last updated 2020-08-18
Summary
The investigators will develop a digital application (app)-"rPlan dual protection" (rPlan)-to be used in the clinic waiting room prior to a gynecological and/or contraceptive visit. The goal of this research is to develop the app and conduct a feasibility, acceptability and effectiveness assessment of rPlan to examine improvement in dual protection behaviors, enhancement of contraceptive adherence and continuation, increase of condom use and decrease of sexually transmitted infection (STI) and human immunodeficiency virus(HIV) infection. The research will consist of baseline activities and a 12-week in-clinic survey and STI test, as well as a retrospective chart review.
Conditions
- Sexually Transmitted Infection
Interventions
- BEHAVIORAL
-
rPlan dual protection waiting room app intervention
Sponsors & Collaborators
-
University of Chicago
lead OTHER
Principal Investigators
-
Melissa Gilliam, MD, MPH · University of Chicago, Dept. of OBGYN
Study Design
- Allocation
- NA
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 15 Years
- Max Age
- 24 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2015-07-31
- Primary Completion
- 2017-06-30
- Completion
- 2017-08-31
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate the Safety and Immunogenicity for Regimen Selection of Ad26.RSV.preF and/or RSV preF Protein Combinations Followed by Expanded Safety Evaluation in Adults Aged 60 Years and Older
NCT03502707 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19
NCT04470427 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19
NCT04813796 ·Status: COMPLETED ·Phase: PHASE1
-
Randomized Single-Blinded Study to Evaluate Safety and Immunogenicity of Recombinant Plague Vaccine With and Without Adjuvant
NCT01122784 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Preliminary Immunogenicity Study of Inactivated Vaccine for Prevention of Rotavirus Infection
NCT04626856 ·Status: UNKNOWN ·Phase: PHASE1
-
A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults
NCT04614948 ·Status: COMPLETED ·Phase: PHASE3
-
Study of a Respiratory Syncytial Virus/Human Metapneumovirus Vaccine Candidate
NCT06134648 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety of RSV Preventive Monoclonal Antibody
NCT07158814 ·Status: RECRUITING ·Phase: PHASE4
-
Evaluation of the Safety of a Polyvalent Virus in Healthy Adults
NCT00187044 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy Participants
NCT06655870 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
NCT04927065 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection
NCT05070546 ·Status: COMPLETED ·Phase: PHASE3
-
Measuring Responses to Sublingual Antigens
NCT00949572 ·Status: COMPLETED ·Phase: NA
-
MEDI-557 Adult Dosing
NCT01562938 ·Status: COMPLETED ·Phase: PHASE1
-
A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers
NCT01769573 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Immunogenicity of the RSV-F Vaccine in Older Adults Previously Treated With the Same Vaccine or Placebo in the Prior Year.
NCT02593071 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age
NCT05992935 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study to Assess the Safety, Effects and Palatability of Sisunatovir in Healthy Adult Participants
NCT05712460 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
NCT07205796 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults
NCT05903118 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers
NCT02125578 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2b/3, Randomized, Observer-Blinded, Placebo-Controlled, Multicenter Clinical Study Evaluating the Efficacy and Safety of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults 18 Years of Age and Older
NCT04652102 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
NCT07117487 ·Status: COMPLETED ·Phase: PHASE3
-
Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction
NCT05212610 ·Status: COMPLETED ·Phase: PHASE4
-
A Study on the Safety and Immune Response of Investigational COVID-19 mRNA Vaccines in Healthy Adults
NCT05960097 ·Status: COMPLETED ·Phase: PHASE2